Addition of Vadastuximab Talirine to 7 + 3 Induction Therapy for Newly Diagnosed AML: Phase Ib Dose-Escalation Trial

Slideset - Results from a phase Ib trial combining vadastuximab talirine to 7 + 3 induction therapy suggests deeper and more rapid remissions, without added nonhematologic toxicity, for patients with newly diagnosed AML.
Source: Clinical Care Options Leukemia - Category: Hematology Source Type: research